In This Article:
Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.
Bio-Techne beat analysts’ revenue expectations by 4.2% last quarter, reporting revenues of $297 million, up 9% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts’ organic revenue estimates and a decent beat of analysts’ EPS estimates.
Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Bio-Techne’s revenue to grow 4.6% year on year to $317.4 million, improving from the 3.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.51 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Bio-Techne’s peers in the research tools & consumables segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Mettler-Toledo’s revenues decreased 4.6% year on year, beating analysts’ expectations by 1%, and Danaher reported flat revenue, topping estimates by 2.7%. Mettler-Toledo traded up 4.3% following the results while Danaher was also up 6.2%.
Read our full analysis of Mettler-Toledo’s results here and Danaher’s results here.
There has been positive sentiment among investors in the research tools & consumables segment, with share prices up 4.4% on average over the last month. Bio-Techne is down 4.8% during the same time and is heading into earnings with an average analyst price target of $79.70 (compared to the current share price of $49.80).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.